# Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

> **NCT01392911** · PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 128 (estimated)

## Conditions studied

- Pulmonary Tuberculosis (TB)

## Interventions

- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01392911
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2018-07
- **Final completion:** 2018-11
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2018-11-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392911, "Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01392911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*